Pressemitteilungen zu dem Thema trillium therapeutics inc


Unterkategorien

PresseMitteilungen zu dem Schlagwort trillium therapeutics inc


Trillium Therapeutics'' TTI-2341 EGFR Inhibitor Program Featured at the Society for Neuro-Oncology 22nd Annual Meeting

TORONTO, ONTARIO -- (Marketwired) -- 11/20/17 -- Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that new preclinical data for its novel covalent EGFR inhibitor were presented at the Society for Neuro-Oncology 22nd Annual Meeting, November 16-19, in San Francisco.Poster Presentation: TTI-2341: A novel, orally bioavailable, brain-penetrant, covalent epidermal growth factor ...


20.11.2017

Trillium Announces Private Placement

TORONTO, ONTARIO -- (Marketwired) -- 11/15/17 -- Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has entered into subscription agreements for the sale of 1,950,000 common shares and 400,000 Series II non-voting convertible first preferred shares at a price of U.S.$8.50 per share, in a non-brokered private placement for gross proceeds of U.S.$19,975,000.Net proceed ...


15.11.2017

Trillium Therapeutics'' TTI-621 Program Featured at the Society for Immunotherapy of Cancer 32nd Annual Meeting

TORONTO, ONTARIO -- (Marketwired) -- 11/13/17 -- Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that new preclinical and clinical data from ongoing Phase 1 a/b trials for its CD47-blocking agent, TTI-621 (SIRPa-IgG1 Fc), were presented this weekend at the Society for Immunotherapy of Cancer 32nd Annual Meeting in National Harbor, Maryland USA.Poster Presentation P42: The ...


13.11.2017

Trillium Therapeutics Reports Third Quarter 2017 Financial and Operating Results

TORONTO, ONTARIO -- (Marketwired) -- 11/10/17 -- Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported financial results for the nine months ended September 30, 2017."Our strategy of running intravenous and intratumoral signal-seeking Phase 1 trials of TTI- 621 in multiple indications gives us the best opportunity to identify malignancies where we can further focus our clin ...


10.11.2017

Trillium Therapeutics to Present at Upcoming Scientific Conferences

TORONTO, ONTARIO -- (Marketwired) -- 11/06/17 -- Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TRIL) a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that the company is scheduled to present an update on the company''s programs and progress at several upcoming scientific conferences.Society for Immunotherapy of Cancer 32nd Annual MeetingPresenter: Lisa Johnson, Ph.D., Trillium Research ScientistTitle: The checkpoin ...


06.11.2017

Trillium Therapeutics'' TTI-621 Program Featured at the EORTC CLTF Cutaneous Lymphoma Conference

TORONTO, ONTARIO -- (Marketwired) -- 10/16/17 -- Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that new preclinical data and a patient case study for its CD47-blocking agent, TTI-621 (SIRPa-IgG1 Fc), were presented at the EORTC CLTF meeting "Cutaneous Lymphomas - Insights and Therapeutic Progress", October 13-15, in London, England.Oral Presentation O-16: CD47 ...


16.10.2017

Trillium Therapeutics Welcomes Dr. Helen Tayton-Martin to Its Board of Directors

TORONTO, ONTARIO -- (Marketwired) -- 10/11/17 -- Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that Dr. Helen Tayton-Martin has been appointed to its board of directors.Dr. Tayton-Martin, Chief Business Officer at Adaptimmune, has over 25 years of experience working within the pharma, biotech and consulting environment in disciplines across preclinical and clinical deve ...


11.10.2017

Trillium Therapeutics Reports Second Quarter 2017 Financial and Operating Results

TORONTO, ONTARIO -- (Marketwired) -- 08/11/17 -- Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today provided a corporate update and reported financial results for the six months ended June 30, 2017."Both our intravenous and intratumoral signal-seeking Phase 1 trials of TTI-621 progressed well this quarter," said Dr. Niclas Stiernholm, Trillium''s Chief Executive Of ...


11.08.2017

Trillium Provides Update on Small Molecule Programs

TORONTO, ONTARIO -- (Marketwired) -- 07/05/17 -- Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today provided an update on its preclinical small molecule programs.Trillium''s small molecule programs are built upon a proprietary fluorine-based chemistry platform. Incorporation of fluorine into small molecules can improve potency, absorption and blood-brain-barrier (BBB) penetr ...


05.07.2017

Trillium Announces Partial Exercise of Over-Allotment Option

TORONTO, ONTARIO -- (Marketwired) -- 06/28/17 -- Trillium Therapeutics Inc. (TSX: TRIL)(NASDAQ: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that the underwriters of its recent public offering have exercised their over-allotment option by purchasing an additional 199,674 common shares at a price of US$5.00 per share, for additional gross proceeds to Trillium of US$998,370. Closing of the partial exercise of the ove ...


28.06.2017

Trillium Expands Clinical Trial With TTI-621 to Include Combination With PD-1 Blockade

TORONTO, ONTARIO -- (Marketwired) -- 06/07/17 -- Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TRIL), a clinical stage immuno-oncology company, today announced that based upon promising early evidence of anti-tumor activity in patients with both myeloid and lymphoid malignancies, it has further expanded its current intravenous dosing trial of TTI-621, an IgG1 SIRPaFc fusion protein targeting CD47.Changes to the trial include:"Having observed meaningful objective responses among multiple t ...


07.06.2017

Trillium Closes US$30 Million Public Offering of Common Shares and Series II Non-Voting Convertible First Preferred Shares

TORONTO, ONTARIO -- (Marketwired) -- 06/01/17 -- Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the closing of its previously announced underwritten public offering of 2,750,000 common shares and 3,250,000 Series II Non-Voting Convertible First Preferred Shares. The common shares were sold at a public offering price of US$5.00 per share and the Series II Non-Voting Conve ...


01.06.2017

Trillium Therapeutics Announces Presentation on TTI-621 Immune Checkpoint Inhibitor Targeting CD47 at 2017 ASCO Annual Meeting

TORONTO, ONTARIO -- (Marketwired) -- 05/31/17 -- Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, will present its TTI-621 (SIRPaFc) immune checkpoint inhibitor program at the Trials in Progress Session of the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held in Chicago from June 2-6.Details of Trillium''s ASCO presentation are as follows:Presentation ...


31.05.2017

Trillium Announces Pricing of US$30.0 Million Public Offering of Common Shares and Series II Non-Voting Convertible First Preference Shares

TORONTO, ONTARIO -- (Marketwired) -- 05/26/17 -- Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has priced its previously announced underwritten public offering of 2,750,000 common shares and 3,250,000 Series II Non-Voting Convertible First Preferred Shares. The common shares are being sold at a public offering price of US$5.00 per share and the Series II Non-Vot ...


26.05.2017

Trillium Announces Proposed Public Offering

TORONTO, ONTARIO -- (Marketwired) -- 05/25/17 -- Trillium Therapeutics Inc. (TSX: TRIL)(NASDAQ: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has commenced a public offering of its common shares and Series II Non-Voting Convertible First Preferred Shares. The Series II Non-Voting Convertible First Preferred Shares are being offered to investors whose purchase of common shares in the offering may result in su ...


25.05.2017

Trillium Reports First Quarter 2017 Financial and Operating Results

TORONTO, ONTARIO -- (Marketwired) -- 05/12/17 -- Trillium Therapeutics Inc. (TSX: TRIL)(NASDAQ: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today provided a corporate update and reported financial results for the three months ended March 31, 2017."With continued strong recruitment at eight clinical sites across North America, we were recently able to provide preliminary observations from our TTI-621 trial in hematologic malig ...


12.05.2017

Trillium Therapeutics to Present at Investor and Scientific Conferences in April

TORONTO, ONTARIO -- (Marketwired) -- 03/29/17 -- Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TRIL) a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that the company is scheduled to present an update on the company''s programs and progress at several upcoming conferences.About Trillium TherapeuticsTrillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatmen ...


29.03.2017

Trillium Reports Annual 2016 Financial and Operating Results

TORONTO, ONTARIO -- (Marketwired) -- 03/10/17 -- Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today provided a corporate update and reported financial results for the year ended December 31, 2016."2016 marked a year of significant clinical progress with our lead drug candidate TTI-621, which completed Phase 1a dose escalation and advanced into Phase 1b cohort expansion in patients ...


10.03.2017

Trillium Therapeutics Provides Additional Details on ASCO-SITC Conference Presentation on TTI-621

TORONTO, ONTARIO -- (Marketwired) -- 02/24/17 -- Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TRIL), a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, today presented new pharmacology data from its ongoing Phase 1 a/b trial of TTI-621, a SIRPaFc fusion protein targeting CD47 in patients with advanced hematologic malignancies. The presentation took place at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.The company prese ...


24.02.2017

Trillium Therapeutics to Present New Data from TTI-621 Phase 1 Trial

TORONTO, ONTARIO -- (Marketwired) -- 02/15/17 -- Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TRIL), a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it will present new data from the Phase 1 trial of its anti-CD47 checkpoint inhibitor TTI-621 at the ASCO-SITC Clinical Immuno-Oncology Symposium on February 24, in Orlando, Florida.The presentation will highlight new pharmacokinetic and pharmacodynamic data from patients ...


15.02.2017

Trillium Therapeutics to Present at Investor and Scientific Conferences in February

TORONTO, ONTARIO -- (Marketwired) -- 02/07/17 -- Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TRIL) a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that the company is scheduled to present an update on the company''s programs and progress at several upcoming conferences.A live audio webcast of this presentation will be available under the investor relations section of Trillium''s website at . A replay of ...


07.02.2017

Trillium Therapeutics Outlines Anticipated Activities and Milestones for 2017

TORONTO, ONTARIO -- (Marketwired) -- 02/02/17 -- Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TRIL), a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, today outlined its expected 2017 activities and milestones.Phase 1 trials of TTI-621:During the year, Trillium expects to make progress in the Phase 1b TTI-621-01 study (NCT02663518) of its anti-CD47 checkpoint inhibitor TTI-621 (SIRPaFc), which is designed to evaluate safety, pharmacokinetics ...


02.02.2017

Trillium Therapeutics Doses First Patient With TTI-621 in Phase 1 Solid Tumor Trial

TORONTO, ONTARIO -- (Marketwired) -- 01/31/17 -- Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TR), a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has initiated dosing in its second Phase 1 clinical trial with TTI-621 (SIRPaFc) in patients with relapsed or refractory percutaneously-accessible solid tumors and mycosis fungoides. Trillium is developing TTI-621 as a novel checkpoint inhibitor of the innate immune syste ...


31.01.2017

Trillium Presents Initial Data From Ongoing Study of TTI-621 in Patients With Advanced Hematologic Malignancies at the American Society of Hematology Annual Meeting

SAN DIEGO, CALIFORNIA -- (Marketwired) -- 12/03/16 -- Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TR), a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, today presented data from an ongoing study with its lead drug candidate, TTI-621, in patients with relapsed or refractory hematologic malignancies, at the American Society of Hematology (ASH) 58(th) Annual Meeting in San Diego."We are encouraged by the initial results from the study of ...


03.12.2016

Trillium Therapeutics Announces Conference Call and Webcast on December 5th to Discuss TTI-621 Data Presented at ASH

TORONTO, ONTARIO -- (Marketwired) -- 11/29/16 -- Trillium Therapeutics Inc. (TSX: TR)(NASDAQ: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it will host a conference call and webcast at 8:30 a.m. ET (5:30 a.m. PT) on Monday, Dec. 5, 2016, to discuss the poster presentation on its lead drug candidate, TTI-621, at the American Society of Hematology (ASH) 58th Annual Meeting in San Diego. Trillium will present init ...


29.11.2016

Trillium Reports Third Quarter 2016 Financial Results and Provides Corporate Update

TORONTO, ONTARIO -- (Marketwired) -- 11/10/16 --Trillium Therapeutics Inc. (Nasdaq: TRIL)(TSX: TR), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today provided a corporate update and reported financial results for the three and nine months ended September 30, 2016."Over the last several months, we''ve continued to advance our lead drug candidate, TTI- 621, in the clinic," said Niclas Stiernholm, president and CEO of Tri ...


10.11.2016

Trillium Therapeutics Announces Investor and Scientific Presentation Schedule for Remainder of 2016

TORONTO, ONTARIO -- (Marketwired) -- 11/03/16 -- Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TR), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, is scheduled to present an update on the company''s programs and progress at several upcoming conferences in 2016.Investor Conference:Scientific Conferences:About Trillium TherapeuticsTrillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies ...


03.11.2016

Trillium Therapeutics Advances TTI-621 Into Phase 1b Cohort Expansion Enrollment

TORONTO, ONTARIO -- (Marketwired) -- 11/02/16 -- Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TR), a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, has advanced its novel investigational drug TTI-621, a SIRPa-IgG1 Fc fusion protein, from dose escalation into Phase 1b cohort expansion enrollment in patients with advanced hematologic malignancies. As part of the advancement, the company provides the following study updates:"TTI-621 is a ...


02.11.2016

Trillium Therapeutics Introduces Industry Postdoctoral Fellowship Program

TORONTO, ONTARIO -- (Marketwired) -- 08/31/16 -- Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TR), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that the company has established an industry postdoctoral fellowship program to help young research scientists transition from their academic training to rewarding careers in the biopharmaceutical industry."As part of our commitment to help grow the Canadian biotechnology in ...


31.08.2016

Trillium Therapeutics to Present at Investor and Scientific Conferences in September

TORONTO, ONTARIO -- (Marketwired) -- 08/23/16 -- Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TR), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that the company is scheduled to present an update on the company''s programs and progress at several upcoming conferences.Investor Conferences:A live audio webcast of each presentation will be available under the investor relations section of Trillium''s webs ...


23.08.2016

Trillium Therapeutics Receives FDA Clearance to Proceed With TTI-621 in Clinical Trial Targeting Solid Tumors and Mycosis Fungoides

TORONTO, ONTARIO -- (Marketwired) -- 08/17/16 -- Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TR), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that the US Food and Drug Administration (FDA) has provided the company clearance to initiate a Phase 1 clinical trial of its lead drug candidate, TTI-621 (SIRPaFc), in solid tumors and mycosis fungoides. Patient enrollment is anticipated to commence by the end of the year. Trill ...


17.08.2016

Trillium Reports Second Quarter 2016 Financial Results

TORONTO, ONTARIO -- (Marketwired) -- 08/12/16 -- Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TR), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today provided a corporate update and reported financial results for the three and six months ended June 30, 2016."Trillium made continued progress in the second quarter, as we advanced the Phase 1 study of our lead drug candidate, TTI-621, in relapsed or refractory hematologic malignancies ...


12.08.2016

Trillium Therapeutics Announces Presentation on TTI-621 Immune Checkpoint Inhibitor Targeting CD47 at European Hematology Association 21st Annual Congress

TORONTO, ONTARIO -- (Marketwired) -- 06/07/16 -- Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TR), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, will present its TTI-621 (SIRPaFc) immune checkpoint inhibitor program at the European Hematology Association 21(st) Annual Congress, to be held in Copenhagen from June 9-12.Details of Trillium''s presentation are as follows:Presentation Type: Electronic PosterAbstract #: E1373Title: T ...


07.06.2016

Trillium Announces Voting Results From the Annual and Special Meeting of Shareholders

TORONTO, ONTARIO -- (Marketwired) -- 05/31/16 -- Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TR), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the voting results from its Annual and Special Meeting of shareholders held on May 27, 2016. The results of the director elections were as follows:The shareholders of the Corporation also voted to reappoint Ernst & Young LLP, Chartered Professional Accountants, Licensed Publi ...


31.05.2016

Trillium Therapeutics Announces Presentation on TTI-621 Immune Checkpoint Inhibitor Targeting CD47 at 2016 ASCO Annual Meeting

TORONTO, ONTARIO -- (Marketwired) -- 05/18/16 -- Trillium Therapeutics Inc. (TSX: TR) (NASDAQ: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, will present its TTI-621 (SIRPaFc) immune checkpoint inhibitor program at the Trials in Progress Session of the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held in Chicago from June 3-7.Details of Trillium''s ASCO presentation are as follows:About Trillium ...


18.05.2016

Trillium Reports First Quarter 2016 Financial Results

TORONTO, ONTARIO -- (Marketwired) -- 05/13/16 -- Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TR), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today provided a corporate update and reported financial results for the three months ended March 31, 2016."We made significant progress during the first quarter of 2016, positioning our oncology pipeline for long-term growth. Firstly, we advanced our lead CD47 clinical program on schedule ...


13.05.2016

Trillium to Provide Update on CD47 Program at the 2016 American Association for Cancer Research Annual Meeting

TORONTO, ONTARIO -- (Marketwired) -- 04/14/16 -- Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TR) an immuno-oncology company developing innovative therapies for the treatment of cancer, today announced it will be providing an update on its SIRPaFc immune checkpoint inhibitor program, targeting the CD47 protein, at the 107th Annual Meeting of the American Association for Cancer Research. The meeting will be held April 16-20, 2016 in New Orleans, LA. Details of the poster presentation, entitled ...


14.04.2016

Trillium to Present at the 2016 Annual Needham Health Care Conference

TORONTO, ONTARIO -- (Marketwired) -- 04/12/16 -- Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TR) a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that Dr. Niclas Stiernholm, President and Chief Executive Officer, will present a corporate overview at the upcoming 15th Annual Needham Healthcare Conference at The Westin Grand Central Hotel in New York, NY, on Wednesday, April 13th at 4:20 pm.About Trillium Therapeutics:Trilliu ...


12.04.2016

Trillium Announces a $3.4 Million Government Co-Funded Translational Research Program

TORONTO, ONTARIO -- (Marketwired) -- 03/10/16 -- Trillium Therapeutics Inc. (NASDAQ: TRIL) (TSX: TR) a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has entered into a collaboration agreement with University Health Network and the Hospital for Sick Children to fund and undertake a research program entitled "SIRPaFc: Translating Genomics Research Into a Novel Cancer Immunotherapy." Importantly, this project h ...


10.03.2016

Trillium to Present at the Cowen and Company 36th Annual Health Care Conference

TORONTO, ONTARIO -- (Marketwired) -- 03/08/16 -- Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TR) a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that Bob Uger, Ph.D., Chief Scientific Officer will present at the Cowen and Company 36th Annual Health Care Conference at The Boston Marriott Copley Place in Boston, MA on Wednesday, March 9th at 11:20 am.Webcast Information:The live webcast of the presentation will be accessible ...


08.03.2016

Trillium Therapeutics Doses First Patient With TTI-621, a Novel Immune Checkpoint Inhibitor Targeting CD47

TORONTO, ONTARIO -- (Marketwired) -- 02/03/16 -- Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TR) a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has initiated dosing in its Phase 1 clinical trial of TTI-621 (SIRPaFc), a novel checkpoint inhibitor of the innate immune system, in relapsed or refractory hematologic malignancies.TTI-621 is an antibody-like fusion protein that blocks the inhibitory activity of CD47, a m ...


03.02.2016

Trillium Acquires Privately-Held Fluorinov Pharma Inc.

TORONTO, ONTARIO -- (Marketwired) -- 01/27/16 -- Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TR) a clinical immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has acquired all of the outstanding shares of Fluorinov Pharma Inc., a privately-held oncology company. Fluorinov has developed a proprietary medicinal chemistry platform using unique fluorine chemistry, which permits the creation of new chemical entities from validated drugs a ...


27.01.2016

Trillium to Provide Update on CD47 Immune Checkpoint Inhibitor Program at the 2015 American Society of Hematology Annual Meeting

TORONTO, ONTARIO -- (Marketwired) -- 12/03/15 -- Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TR) an immuno-oncology company developing innovative therapies for the treatment of cancer, today announced it will be providing an update on its SIRPaFc immune checkpoint inhibitor program targeting CD47 at the 57th Annual Meeting of the American Society of Hematology. Details of the poster presentation, entitled "SIRPaFc, a CD47-Blocking Cancer Immunotherapeutic, Sensitizes Malignant B cells ...


03.12.2015

Trillium Therapeutics Provides Update on CD47 Program

TORONTO, ONTARIO -- (Marketwired) -- 09/30/15 -- Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TR), an immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has completed the manufacture of clinical-grade drug product, concluded a comprehensive IND-enabling non-clinical safety assessment program, and has proposed a design for its first-in-human clinical trial with TTI-621 (SIRPaFc).The Company plans to conduct a Phase I trial with a dose- ...


30.09.2015

Stem Cell Therapeutics Announces Agreement With Trillium Therapeutics Inc. for Merger

TORONTO, ONTARIO -- (Marketwire) -- 02/04/13 -- Stem Cell Therapeutics Corp. (TSX VENTURE: SSS), a life sciences company developing stem cell-related technologies, today announced the execution of a Letter of Agreement with Trillium Therapeutics Inc. ("Trillium") of Toronto, under which Trillium would be merged into Stem Cell Therapeutics Corp. ("SCT") by way of a three-cornered amalgamation or plan of arrangement with a newly-created SCT subsidiary.In addition, SCT announc ...


04.02.2013

Trillium Announces Voting Results from the Annual Meeting of Shareholders

TORONTO, ONTARIO -- (Marketwired) -- 05/26/17 -- Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the voting results from its Annual Meeting of shareholders held today. The results of the director elections were as follows:The shareholders of the Corporation also voted to reappoint Ernst & Young LLP, Chartered Professional Accountants, Licensed Public Accountants as au ...


26.05.2017

Trillium Reports 2015 Financial and Operating Results

TORONTO, ONTARIO -- (Marketwired) -- 03/09/16 -- Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TR) a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reports financial results for the year ended December 31, 2015 and provides a corporate update."2015 was a pivotal year for Trillium with the successful advancement of TTI-621, our checkpoint inhibitor targeting CD47, into human clinical trials in patients with advanced hematologic mal ...


09.03.2016



All members: 9 438
Register today: 0
Register yesterday: 0
Members online: 0
Guests online: 52


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.